Welcome to Nofinity

This video explains why tokenized stocks (RWAs) are revolutionizing the stock market. They offer 24/7 trading, lower fees, faster settlement, and transparency via the blockchain. Traditional stocks are limited to exchange hours and require multiple intermediaries.

Problems of the First Generation of Tokenized Stocks

• No real shareholder rights (no voting rights, ownership stays with the custodian)
• Low liquidity (thin secondary markets, wide spreads)
• Regulatory uncertainty and high complexity due to cross-chain bridges

BitGet's Stock 2.0 Model

BitGet introduced two products: Stock Plus and R Tokens.

• Stock Plus: Enables direct ownership of over 10,000 stocks. You invest directly, receive cash dividends, and can transfer stocks from other brokers.
• R Tokens: Tokenized US stocks and ETFs that track the price 1:1. No direct ownership, but compatible with DeFi (use as collateral, futures, copy trading, grid trading). You receive dividends automatically in USDT.

Benefits of R Tokens on BitGet

• One account for crypto and tokenized stocks
• Automated strategies via trading bots (Auto Invest, Smart Portfolios)
• First Cross-Asset Unified Account (UTA): Over 370 tokenized assets in a single margin pool
• Commission-free trading for R tokens, no management fees
• Up to $500,000 SIPC protection through the partner broker Alpaca

Risks & Conclusion

R tokens do not offer voting rights, dividends may be subject to deductions, and trading is not always 24/7. Using them as collateral carries liquidation risks. However, the potential is huge: Even a 1% tokenization of global stocks creates a multi-trillion dollar market by 2030. BitGet's Stock 2.0 could take a leading role.

Expert opinion: CEO Gracie Chen predicts that about 10% of all financial assets will be tokenized by 2030.

This video demonstrates how to build an AI trading bot that mimics Warren Buffett's investment strategy, using the open-source "AI Hedge Fund" project on GitHub. The bot leverages Claude (Fable 5.1) and real-time financial data (e.g., from Financial Datasets) to analyze stocks and execute trades.

Key Steps & Results:

• Stock Analysis: The AI Buffett rated Apple as neutral (60% confidence) and Nvidia cautiously (due to margin concerns). Coca-Cola received the highest confidence (68%).
• Portfolio Construction: With a simulated $100,000 fund, the bot selected 24 stocks from the S&P 500 top 100. Top holding: Microsoft; smallest: IBM. Only 3% cash.
• Backtest (Sept. 2024 to present): The AI Buffett outperformed the S&P 500 with a return of 39.2% vs. 34.8% and a lower max drawdown (5.8% vs. 8%). Best performer: Alphabet (+114%); worst: Accenture (-$2,000).
• Automation: The bot can be connected to an Alpaca paper trading account via API for automatic order execution. Persistent operation on a VPS is supported.

Conclusion:

The simulation suggests an AI model based on Buffett's approach can beat the market — at least in backtesting. However, the creator warns against entrusting real savings to such a bot. The project is intended as an experiment and learning tool.

Summary follows...

The 2 Amino Acids That Restore Muscle Strength & Burn 78% More Fat

This summary analyzes a study on GlyNAC (Glycine + N-Acetylcysteine) and its effects on mitochondrial health, muscle strength, and fat metabolism in older adults.

• Mitochondrial Dysfunction: Aging muscle cells lose the ability to efficiently burn fatty acids.
• Glutathione Deficiency: Intracellular glutathione, the cell's master antioxidant, is reduced by up to 70% in older adults.
• Root Cause: Two rate-limiting building blocks – glycine and cysteine – are equally depleted with age.

• Mechanism: The cell needs both amino acids to produce glutathione. Glycine and NAC provide the missing components.
• Study Design: 24 overweight older adults (61-80 years) received 100 mg/kg glycine + 100 mg/kg NAC daily (approximately 9 g per amino acid for a 90 kg person) for 16 weeks.

• Glutathione Increase: +225% in red blood cells, +164% in muscle biopsies – reaching levels of young adults.
• Fat Oxidation: +78% increase.
• Muscle Strength:
  • Gait Speed: +0.21 m/s (matching young adult levels)
  • Grip Strength: +4.4 kg (dominant hand)
  • Chair Rise Test: -6.8 seconds (better leg power)
• No Muscle Gain: Lean mass remained unchanged. Strength gains resulted from improved mitochondrial efficiency.

• Anti-Inflammatory: Interleukin-6 decreased by 78%, TNF-alpha by 54%, protective interleukin-10 nearly doubled.
• Insulin Resistance: HOMA-IR decreased by 64%.
• Oxidative Stress: DNA damage markers dropped by 73%.
• Blood Pressure: Systolic decreased from 132 to 124 mmHg.

• High Dosage: The study used very high doses (18 g of amino acids daily). Lower doses have not been tested.
• No Sustained Effect: After stopping GlyNAC, glutathione levels and strength gains returned to baseline.
• Lifespan Extension: The often-cited 24% lifespan increase comes from a mouse study, not human data.

GlyNAC addresses a core cause of age-related strength and energy loss: glutathione deficiency. The results are promising but require medical supervision, especially at high doses and regarding potential drug interactions.

• A 49-year-old sets the ambitious goal to dunk a basketball – a symbol of youthful athleticism and vitality.
• He trains with a professional coach who works with NBA players and has been at it for nearly 3 months.

• Instead of abstract metrics like VO2max (which he previously pushed to elite 18-year-old levels), he now focuses on a visible, relatable target.
• A dunk resonates with people: „The best biomarker I could ever achieve.“

• Phase 1 (first 2 months): Build a strong physiological base – especially tendon health and stiffness (tendons adapt in 8–12 weeks, muscles in 3–4).
• Phase 2 (from month 3): Add strength (for force production) and later speed (rate of force development).
• Current vertical jump measurement: 23.9 inches (approx. 60.7 cm) – baseline.

• After 3 months he feels clear gains and more trust in his body.
• The coach estimates an 80–85% success probability – aided by lean physique, good nutrition and sleep.
• Key: precise execution of drills (e.g., knees over toes in squats, bouncy movements).

„It‘s not about stopping the negative, it‘s about doing the positive.“ – The journey to a dunk is a statement against age limits.

• Clarity Act Fails: The first major US crypto regulation bill died in the Senate (49:50, 10 votes short). Coinbase stock fell 8%, Circle ~10%. Bitcoin ignored it.
• Fed Rate Hike: The US Federal Reserve raised rates by 25 basis points (first since 2023). The 10-year Treasury yield spiked above 5%, the Bank of Japan hiked to a 31-year high. Bitcoin still rose.
• AI Sector Weakens: Anthropic's CEO warned about runaway AI progress. Sam Altman and Elon Musk agreed. The semiconductor index dropped over 5%; Nvidia, ASML, SoftBank all fell. Crypto remained unfazed.

• 84% of liquidations were shorts ($843M of $1B total).
• In a single hour, over $300M was liquidated, 97% of it shorts.
• Between 126,000 and 135,000 accounts were closed.
• One wallet lost 375 BTC (~$32.5M) in four sequential liquidations over 14 hours.
• Mechanics: Forced buying from short liquidations pushes price higher → triggers next layer of shorts → cascade.

• Clarity Act irrelevant for markets: A failed bill changes nothing about Bitcoin's functionality (blocks, trades, custody). Crypto grew to over $1 trillion without US regulation.
• Institutions keep buying:
  • Strategy (MicroStrategy) bought 950 BTC for $75M right in the worst news week.
  • US spot Bitcoin ETFs lost $450M on voting day, but regained $433M just three sessions later.
  • Morgan Stanley's Bitcoin ETF logged 20 consecutive days of net inflows.

• China ban 2021: >50% of global hashrate went offline → Bitcoin rose from $29K to new ATH in 4 months.
• FTX collapse Nov 2022: Low of $15,400 – the absolute bottom.
• US banking crisis March 2023: Three banks failed, USDC depegged → Bitcoin rallied 40%.
• Inverse: Coinbase IPO April 2021 (peak) and ETF approval January 2024 (price fell from 49K to 38K) – good news marked tops.

Bitcoin is not a market that only rises on good news. The current rally through three parallel shocks shows: A strong holder base and institutional demand drive price independently of politics and macro. Future headlines may be just as grim – but crypto has proven itself through years of uncertainty and hostility. The question: Higher from here, or a bull trap?

Kaspi.kz (NASDAQ: KSPI) is a super app from Kazakhstan that covers nearly the entire financial and daily life of the country. The stock offers a dividend yield of almost 9 %, a P/E ratio of about 7, and growth of around 17 % – for the analyst, it's hard to find much wrong.

• Monopoly position: 85 % of payment processing and 70 % market share in consumer commerce in Kazakhstan.
• Government integration: Deep cooperation with the government and central bank – considered “too big to fail.” After a short-seller report (Culper Research), regulators immediately defended the company.
• Super app: Used for healthcare, government services, and banking – practically the entire population depends on it.
• Monopoly with political backing: This only works in Kazakhstan, but there it is a legal money-printing machine.

• Acquisition of Turkish e-commerce leader Hepsiburada for $1.1 billion.
• Acquisition of a banking license (Rabobank license) and planned capital injection of $300 million.
• Expansion of a “Buy Now, Pay Later” business and integration of fintech solutions into the Turkish platform.
• If Turkish profitability even approaches Kazakh levels, this could become a major winner.

• Net income is growing, stable net margin of around 27 %.
• E-commerce growth and payment business are strong thanks to the monopoly position.
• Non-performing loans (NPL): About 6–7 % and slightly rising – worth watching, but cushioned by high interest rates (15 % central bank rate).
• Balance sheet: $15 billion in customer loans, $17 billion in customer deposits – typical bank risks, but with fintech margins.

• Kazakhstan risk: Political connections, corruption allegations, possible rumors about bank stability.
• Dependence on the state: If political support changes, the business model would be in danger.
• Currency risk: Tenge fluctuations, but growth remains strong when measured in dollars.
• Bank risk: As a financial company, always vulnerable to loss of confidence and potential bank runs.

• P/E of 8 with 15 % growth and an 8–9 % dividend yield provide a margin of safety.
• Tencent as an investor and the “Silk Belt and Road” connection to China are additional strategic pluses.
• Founders own 66 % of the capital – without them the construct would not work, which creates resilience.
• The analyst is considering adding the stock to his diversified portfolio, although he considers the environment risky. “Hard to find much wrong” – but it remains an engaged emerging-market investment.